216 related articles for article (PubMed ID: 32015491)
1. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.
Blakemore SJ; Clifford R; Parker H; Antoniou P; Stec-Dziedzic E; Larrayoz M; Davis Z; Kadalyayil L; Colins A; Robbe P; Vavoulis D; Forster J; Carr L; Morilla R; Else M; Bryant D; McCarthy H; Walewska RJ; Steele AJ; Chan J; Speight G; Stankovic T; Cragg MS; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Schuh A; Strefford JC
Leukemia; 2020 Jul; 34(7):1760-1774. PubMed ID: 32015491
[TBL] [Abstract][Full Text] [Related]
2. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
Rose-Zerilli MJ; Forster J; Parker H; Parker A; Rodríguez AE; Chaplin T; Gardiner A; Steele AJ; Collins A; Young BD; Skowronska A; Catovsky D; Stankovic T; Oscier DG; Strefford JC
Haematologica; 2014 Apr; 99(4):736-42. PubMed ID: 24584352
[TBL] [Abstract][Full Text] [Related]
3. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
4. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
[TBL] [Abstract][Full Text] [Related]
5. A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
Chauzeix J; Pastoret C; Donaty L; Gachard N; Fest T; Feuillard J; Rizzo D
Int J Lab Hematol; 2021 Aug; 43(4):683-692. PubMed ID: 33325634
[TBL] [Abstract][Full Text] [Related]
6. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
Lin K; Adamson J; Johnson GG; Carter A; Oates M; Wade R; Richards S; Gonzalez D; Matutes E; Dearden C; Oscier DG; Catovsky D; Pettitt AR
Clin Cancer Res; 2012 Aug; 18(15):4191-200. PubMed ID: 22675167
[TBL] [Abstract][Full Text] [Related]
7. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
Gonzalez D; Martinez P; Wade R; Hockley S; Oscier D; Matutes E; Dearden CE; Richards SM; Catovsky D; Morgan GJ
J Clin Oncol; 2011 Jun; 29(16):2223-9. PubMed ID: 21483000
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
Oscier DG; Rose-Zerilli MJ; Winkelmann N; Gonzalez de Castro D; Gomez B; Forster J; Parker H; Parker A; Gardiner A; Collins A; Else M; Cross NC; Catovsky D; Strefford JC
Blood; 2013 Jan; 121(3):468-75. PubMed ID: 23086750
[TBL] [Abstract][Full Text] [Related]
11. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
[TBL] [Abstract][Full Text] [Related]
12. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
Ljungström V; Cortese D; Young E; Pandzic T; Mansouri L; Plevova K; Ntoufa S; Baliakas P; Clifford R; Sutton LA; Blakemore SJ; Stavroyianni N; Agathangelidis A; Rossi D; Höglund M; Kotaskova J; Juliusson G; Belessi C; Chiorazzi N; Panagiotidis P; Langerak AW; Smedby KE; Oscier D; Gaidano G; Schuh A; Davi F; Pott C; Strefford JC; Trentin L; Pospisilova S; Ghia P; Stamatopoulos K; Sjöblom T; Rosenquist R
Blood; 2016 Feb; 127(8):1007-16. PubMed ID: 26675346
[TBL] [Abstract][Full Text] [Related]
13.
Bomben R; Rossi FM; Vit F; Bittolo T; D'Agaro T; Zucchetto A; Tissino E; Pozzo F; Vendramini E; Degan M; Zaina E; Cattarossi I; Varaschin P; Nanni P; Berton M; Braida A; Polesel J; Cohen JA; Santinelli E; Biagi A; Gentile M; Morabito F; Fronza G; Pozzato G; D'Arena G; Olivieri J; Bulian P; Pepper C; Hockaday A; Schuh A; Hillmen P; Rossi D; Chiarenza A; Zaja F; Di Raimondo F; Del Poeta G; Gattei V
Clin Cancer Res; 2021 Oct; 27(20):5566-5575. PubMed ID: 34285062
[TBL] [Abstract][Full Text] [Related]
14. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
[TBL] [Abstract][Full Text] [Related]
15. Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
Pepper AGS; Zucchetto A; Norris K; Tissino E; Polesel J; Soe Z; Allsup D; Hockaday A; Ow PL; Hillmen P; Rawstron A; Catovsky D; Bulian P; Bomben R; Baird DM; Fegan CD; Gattei V; Pepper C
Leukemia; 2022 Jan; 36(1):271-274. PubMed ID: 34148055
[No Abstract] [Full Text] [Related]
16. Biological and clinical implications of
Diop F; Moia R; Favini C; Spaccarotella E; De Paoli L; Bruscaggin A; Spina V; Terzi-di-Bergamo L; Arruga F; Tarantelli C; Deambrogi C; Rasi S; Adhinaveni R; Patriarca A; Favini S; Sagiraju S; Jabangwe C; Kodipad AA; Peroni D; Mauro FR; Giudice ID; Forconi F; Cortelezzi A; Zaja F; Bomben R; Rossi FM; Visco C; Chiarenza A; Rigolin GM; Marasca R; Coscia M; Perbellini O; Tedeschi A; Laurenti L; Motta M; Donaldson D; Weir P; Mills K; Thornton P; Lawless S; Bertoni F; Poeta GD; Cuneo A; Follenzi A; Gattei V; Boldorini RL; Catherwood M; Deaglio S; Foà R; Gaidano G; Rossi D
Haematologica; 2020; 105(2):448-456. PubMed ID: 31371416
[No Abstract] [Full Text] [Related]
17. Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.
Lozano-Santos C; García-Vela JA; Pérez-Sanz N; Nova-Gurumeta S; Fernandez-Cuevas B; Gomez-Lozano N; Sánchez-Beato M; Sanchez-Godoy P; Bueno JL; Garcia-Marco JA
Leuk Lymphoma; 2017 Apr; 58(4):859-865. PubMed ID: 27499002
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
[TBL] [Abstract][Full Text] [Related]
19. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
[TBL] [Abstract][Full Text] [Related]
20. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Schlette EJ; Admirand J; Wierda W; Abruzzo L; Lin KI; O'Brien S; Lerner S; Keating MJ; Tam C
Leuk Lymphoma; 2009 Oct; 50(10):1597-605. PubMed ID: 19863337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
